Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986712 · ClinicalTrials.gov registry record
A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma
A clinical trial of Melanoma, sponsored by St. Luke's Hospital and Health Network, Pennsylvania.
- Completed
- Registry status
- 50
- Enrollment target
- 4
- Study locations
NCT01986712 is a study of Melanoma that has completed, run by St. Luke's Hospital and Health Network, Pennsylvania. The registered enrollment target is 50 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01986712, a study of Melanoma, has completed, sponsored by St. Luke's Hospital and Health Network, Pennsylvania.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
To evaluate the compliance with and perceptions of treatment, as well as health-related quality of life (HRQOL) in surgically resected melanoma patients undergoing HDI or PEG IFN therapy.
Conditions Studied
Study Locations (4)
Florida
- Moffit Cancer Center - Tampa
New York
- Roswell Park Cancer Institute - Buffalo
Pennsylvania
- St Luke's University Hospital and Health Network - Bethlehem
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-12 |
| Est. Completion | 2019-09-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01986712
The ClinicalTrials.gov registry entry for NCT01986712 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The listed sponsor is St. Luke's Hospital and Health Network, Pennsylvania, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT01986712 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01986712 about?
NCT01986712 is a clinical study titled "A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma". To evaluate the compliance with and perceptions of treatment, as well as health-related quality of life (HRQOL) in surgically resected melanoma patients undergoing HDI or PEG IFN therapy.
What is the current status of trial NCT01986712?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2013-12. Estimated completion is 2019-09-17.
What conditions does trial NCT01986712 study?
This clinical trial studies the following conditions: Melanoma.
Who is sponsoring clinical trial NCT01986712?
This trial is sponsored by St. Luke's Hospital and Health Network, Pennsylvania, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01986712 being conducted?
This trial has 4 study locations across Florida, New York, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.